223 related articles for article (PubMed ID: 29895542)
1. Persistent elevation of carcinoembryonic antigen as first presentation of a medullary thyroid carcinoma.
Martins A; Gonçalves A; Almeida T; Midões A
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29895542
[TBL] [Abstract][Full Text] [Related]
2. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
3. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
4. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
5. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
7. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype.
Murphy DC; Johnson SJ; Aspinall S
Ann R Coll Surg Engl; 2020 Mar; 102(3):e63-e66. PubMed ID: 31841033
[TBL] [Abstract][Full Text] [Related]
9. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
11. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of medullary thyroid cancer in the prediction of cure after thyroidectomy.
Nien FJ; Chang TC
J Formos Med Assoc; 2015 Sep; 114(9):793-4. PubMed ID: 23906686
[No Abstract] [Full Text] [Related]
13. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
14. Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature.
Appetecchia M; Barnabei A; Pompeo V; Sentinelli S; Baldelli R; Corsello SM; Torino F
BMC Endocr Disord; 2014 Oct; 14():84. PubMed ID: 25306429
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Challenges of Medullary Thyroid Carcinoma.
Leimbach RD; Hoang TD; Shakir MKM
Oncology; 2021; 99(7):422-432. PubMed ID: 33878761
[TBL] [Abstract][Full Text] [Related]
16. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
17. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
18. Rising CEA levels in a patient with colon carcinoma: metachronous medullary thyroid cancer.
Göksu SS; Göksu UA; Gündüz S; Coskun HS
Int J Biol Markers; 2014 Jun; 29(2):e184-6. PubMed ID: 24425322
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
